Clinical trial
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With…
NCT00091377 · MEI Pharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00091377 |
|---|---|
| Title | Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| Official title | Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant |
| Lead sponsor | MEI Pharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, paclitaxel, phenoxodiol |
| Enrollment | 65 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Sep 9, 2004 |
| Last update posted | Jul 14, 2016 |
| Countries | Australia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: